CI
SGMO

Cowen Inc’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Cowen Inc’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-11,200
Closed -$121K – 287
2014
Q3 		$121K Buy
+11,200
New +$146K 0.01% 273

Other funds holding SGMO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cowen Inc's SGMO Position: Q4 2014 in Review

Cowen Inc sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2014, closing a stake of 11,200 shares — an estimated $121K sold.

Cowen Inc first reported a position in SGMO in Q3 2014 and held it in 1 quarter. The position peaked at $121K in Q3 2014. 158 funds tracked by Wall St. Rank hold SGMO as of Q4 2014.

  • Cowen Inc reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2014 after selling out during the quarter.
  • Cowen Inc sold 11,200 SANGAMO THERAPEUTICS INC shares in Q4 2014, an estimated $121K.
  • Cowen Inc first reported a position in SANGAMO THERAPEUTICS INC in Q3 2014 and held it in 1 quarter.
  • Cowen Inc's SANGAMO THERAPEUTICS INC position peaked at $121K in Q3 2014.
  • 158 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2014.

Based on Cowen Inc's 13F filing for Q4 2014, filed 17 Feb 2015.